Review Article

Pharmacodynamics of cannabinoids

Alexandra Sulcova*

Published: 08 July, 2019 | Volume 3 - Issue 1 | Pages: 011-018

“Pharmacodynamics of cannabinoids “(i.e. a set of biological effects elicited in the living organism by interaction with its biochemical and biophysical functions up to the cellular level) is studied for a long time during both, physiological and pathological conditions. Cannabinoids received their names according to their natural occurrence as constituents of Cannabis sativa L. (marijuana). 

Read Full Article HTML DOI: 10.29328/journal.apps.1001013 Cite this Article Read Full Article PDF


  1. Turner CE, Elsohly MA, Boeren EG. Constituents of Cannabis sativa L. XVII. A Review of the Natural Constituents. Nat Prod. 1980; 43: 169–234. Ref.: https://tinyurl.com/y29w5az5
  2. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964; 86: 1646–1647. Ref.: https://tinyurl.com/y2nhb5vo
  3. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988; 34: 605–613. Ref.: https://tinyurl.com/y389wtlb
  4. Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992; 258: 1946–1949. Ref.: https://tinyurl.com/yyuoa682
  5. Hanuš L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A. 2001; 98: 3662-3665. Ref.: https://tinyurl.com/y6ytxvzs
  6. Bisogno T, Melck D, Bobrov MYU, Gretskaya NM, Bezuglov VV, et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J. 2000; 1: 817-824. Ref.: https://tinyurl.com/y3p5aeh7
  7. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, et al. Characterization of a novel endocannabinoid virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther. 2002; 301: 1020-1024. Ref.: https://tinyurl.com/y4agwg3w
  8. Munro S, Thomas KL, Abz-shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365: 61–65. Ref.: https://tinyurl.com/yymad43s
  9. Tang XL, Wang Y, Li DL, Luo J, Liu MY. Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets. Acta Pharmacol Sin. 2012; 33: 363–371. Ref.: https://tinyurl.com/y66pcw3t
  10. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001; 134: 845-852. Ref.: https://tinyurl.com/y2ansgx2
  11. Storozhuk MV, Zholos AV. TRP Channels as Novel Targets for Endogenous Ligands: Focus on Endocannabinoids and Nociceptive Signalling. Curr Neuropharmacol. 2018; 16: 137-150. Ref.: https://tinyurl.com/y5ccw5pm
  12. Bridgeman MB, Abazia DT. Medicinal Cannabis: History, Pharmacology, and Implications for the Acute Care Setting. P T. 2017; 42: 180–188. Ref.: https://tinyurl.com/y3b86m7o
  13. Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 1998; 21: 521–528. Ref.: https://tinyurl.com/yyd9lccd
  14. Fišar Z. Chem Listy. 2006; 100: 314−322.
  15. Carvalho AF, Mackie K, Van Bockstaele EJ. Cannabinoid modulation of limbic forebrain noradrenergic circuitry. Eur J Neurosci. 2010; 31: 286-301. Ref.: https://tinyurl.com/y55pfh4a
  16. Castillo PE, Thomas J, Younts TJ, Andrés E, Chávez AE, et al. Endocannabinoid Signaling and Synaptic Function. Neuron. 2012; 76: 70-81. Ref.: https://tinyurl.com/y3rj7dpj
  17. Mackie K. Cannabinoid receptor homo- and heterodimerization. Life Sci. 2005; 77: 1667-1673. Ref.: https://tinyurl.com/yy9ttwev
  18. Di Marzo V, Wang J. The endocannabinoidome. Academic Press, London. 2015.
  19. Zendulka O, Dovrtělová G, Nosková K, Turjap M, Šulcová A, et al. Cannabinoids and Cytochrome P450 Interactions. Curr Drug Metab. 2016; 17: 210-226. Ref.: https://tinyurl.com/yxf2nrxe
  20. Rodríguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, et al. The endocannabinoid system: physiology and pharmacology. Alcohol. 2005; 40: 2-14. Ref.: https://tinyurl.com/y5ge6gm2
  21. Schrot RJ, Hubbard JR. Cannabinoids: Medical implications. Ann Med. 2016; 48: 128–141. Ref.: https://tinyurl.com/y5ykxmfz
  22. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol. 1998; 17: 353: 23-31. Ref.: https://tinyurl.com/y3lrhnca
  23. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects. Br J Pharmacol. 2011; 163: 1344-1364. Ref.: https://tinyurl.com/y5s4qlr2
  24. Chen A. Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects. Br J Pharmacol. 2017; 163: 1344-1364.
  25. Pamplona FA, Rolim da Silva L, Coan AC. Potential Clinical Benefits of CBD-Rich Cannabis Extracts over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Front Neurol. 2018; 9: 759. Ref.: https://tinyurl.com/y48eyvl2
  26. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Internal Med. 2018; 49: 12–19. Ref.: https://tinyurl.com/y47suqjv
  27. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003; 4: 873-884. Ref.: https://tinyurl.com/y5w8seus
  28. Bridgeman MB. Abazia DT. Medicinal Cannabis: History, Pharmacology, and Implications for the Acute Care Setting. P T. 2017; 42: 180–188. Ref.: https://tinyurl.com/yyd9feq3
  29. Le Boisselier R, Alexandre J, Lelong-Boulouard V, Debruyne D: Focus on cannabinoids and synthetic cannabinoids. Clin Pharmacol Ther. 2017; 101: 220-229. Ref.: https://tinyurl.com/y23yqjr3
  30. Morales P, Hurst DP, Reggio PH. Molecular Targets of the Phytocannabinoids: A Complex Picture. Prog Chem Org Nat Prod. 2017; 103: 103-131. Ref.: https://tinyurl.com/yy7dbxhx
  31. Preedy VR. Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment, Academic Press. 2016. Ref.: https://tinyurl.com/yc7hxoz9
  32. Adams R, Hunt M, Clark JH. Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. J Am Chem Soc. 1940; 62: 196–200. Ref.: https://tinyurl.com/y56eub2d
  33. Mechoulam R, Shvo Y. Hashish I: The structure of cannabidiol. Tetrahedron. 1963; 19: 2073–2078. Ref.: https://tinyurl.com/yyqaqw7b
  34. Abrams DI. The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. Eur J Int Med. 2018; 49: 7-11. Ref.: https://tinyurl.com/y67jjkhp
  35. Laprairie RB, Kelly MEM, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015; 172: 4790–4805. Ref.: https://tinyurl.com/y3gb6v86
  36. Rodríguez-Muñoz María, Onetti Yara, Cortés-Montero Elsa, Garzón Javier, Sánchez Blázquez Pilar. Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor. Mol Brain. 2018; 11: 51. Ref.: https://tinyurl.com/y279ucwl
  37. Volkow ND. National Institute on Drug Abuse (NIDA): Marijuana, June 2018.
  38. Barrett JE, Coyle JT. The Neuropsychiatric translational revolution still very early and still very challenging. JAMA Psychiatry. 2013; 70: 777–779. Ref.: https://tinyurl.com/y38m7b9l
  39. Crippa JA, Guimarães FS, Alline C, Campos AC, Zuardi AW. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Front Immunol. 2018; 9: 2009. Ref.: https://tinyurl.com/yxbpnlr6
  40. Piomelli D. Neurobiology of marijuana. V: Textbook of Substance Abuse Treatment, M. Galanter, H. D. Kleber, and K. T. Brady, eds., Arlington VA: American Psychiatric Publishing. 2015; 335–350.
  41. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016; 3: 760–773. Ref.: https://tinyurl.com/yy6upqaf
  42. Zahra A, Burns J, Kure Liu Ch, Manza P, Wiers CE, et al. Cannabis Addiction and the Brain: a Review. J Neuroimmune Pharmacol. 2018; 13: 438-452. Ref.: https://tinyurl.com/y3lbtcfm
  43. Grotenhermen F, Müller-Vahl K. Medicinal Uses of Marijuana and Cannabinoids. Critical Reviews in Plant Sciences. 2016; 35: 378-405. Ref.: https://tinyurl.com/y2sykdju
  44. Šulcová A. Posuzování terapeutického potenciálu a prevence nežádoucích účinků kanabinoidů. Moderní medicína – prevence nebo léčba? Cyril Höschl (ed.), Richard Rokyta (ed.); Axonite. 2017; 54-58.
  45. Zábranský T, Hanuš L, Rokyta R. Přehled současných znalostí o léčebných účincích konopí a přípravků z něj a jeho perspektiv - 2. část. Bulletin sdružení praktických lékařů ČR. 2017; 27: 12-30. Ref.: https://tinyurl.com/yygubvox
  46. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015; 313: 2456-2473. Ref.: https://tinyurl.com/y9kvn7jm
  47. Alexander SP. Review: Therapeutic potential of cannabis-related drugs. Prog NeuroPsychopharmacol Biol Psychiatry. 2016; 64: 157–166. Ref.: https://tinyurl.com/y5chaxar
  48. Mouhamed Y, Vishnyakov A, Qorri B, Sambi M, Frank SMS, et al. REVIEW Therapeutic potential of medicinal marijuana: an educational primer for health care professionals. Drug Healthc Patient Saf. 2018; 11: 45-66. Ref.: https://tinyurl.com/y4kkb899
  49. Mücke M, Weier M, Christopher Carter CH, Copelan J, Degenhard L, et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle. 2018; 9: 220-234. Ref.: https://tinyurl.com/y3jcq4f2
  50. Nolen RS. With pet owners already using the drug as medicine, veterinarians need to join the debate. J Am Vet Med Assoc. 2013; 242: 1604-1609. Ref.: https://tinyurl.com/y3fs3hey
  51. Landa L, Šulcová A, Gbelec P. The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review. Veterinární Medicina. 2016; 3: 111-122. Ref.: https://tinyurl.com/y4sza6fw
  52. Marnett LJ. Decoding endocannabinoid signaling. Nature Chemical Biology. 2009; 5: 8–9. Ref.: https://tinyurl.com/y2x3z4h5.
  53. Zábranský T, Hanuš L, Rokyta R. Overview of current knowledge about the healing effects of cannabis and its preparations and its perspectives. 2016; 26: 10-26. Ref.: https://tinyurl.com/yygubvox
  54. Zábranský T., Hanuš L., Rokyta R. Review of Contemporary Knowledge of the Treatment Effects of Cannabis and Related Products and Its Outlook. 2017; Ref.: https://tinyurl.com/y3b3d99y
  55. Zábranský T, Hanuš L, Rokyta R. Some of the Parts: Is Marijuana's "Entourage Effect" Scientifically Valid?" Scientific American Retrieved. 2017; 12-13. Ref.: https://tinyurl.com/lzouj5a
  56. Wollner HJ, Matchett JR, Loewe S. Isolation of a Physiologically Active Tetrahydrocannabinol from Cannabis Sativa Resin. J Am Chem Soc. 1942; 64: 26–29. Ref.: https://tinyurl.com/y23c5b79

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More